Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — H1 2025/26 Earnings Presentation
10 slides from Coloplast A/s Class B's earnings presentation, 2025
Slide 1: Conference call presentation H1 2025/26: Making life easier
Conference call presentation H1 2025/26 Making life easier Impact4: Setting the standard of care at scale Marque | User, Interventional Urology
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Gavin Wood, President & CEO
Gavin Wood, President & CEO Biography Employment Company Group Chairman, MedTech EMEA, Johnson & Johnson - 2022-2026 Responsible for leading a multibillion-dollar business with more than 7,000 employees. Worldwide President, Wound Closure & Healing, Ethicon - 2019-2022 Responsible for the innovation
Slide 4: Q2 2025/26 financial result
Q2 2025/26 financial result Organic EBIT growth ROIC growth in constant currencies 6% 6% * * 15% ** *before special items and in constant currencies Dorote | User, Continence Care **after tax and before special items. 4
Slide 5: H1 organic growth of 6% driven by Chronic Care and Interventional Urology
H1 organic growth of 6% driven by Chronic Care and Interventional Urology. Wound & Tissue Repair limited contribution in challenging H1 H1 2025/26 revenue by business area H1 2025/26 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic gr
Slide 6: Reported revenue in H1 grew 1%, with 4%-points negative impact from currencies
Reported revenue in H1 grew 1%, with 4%-points negative impact from currencies and 0.5%-point detraction from Skin Care divestment H1 2025/26 Revenue development (mDKK) H1 2025/26 highlights • Reported revenue increased by DKK 171 million or 1% vs. last year. • Organic growth was 6% or DKK 789 milli
Slide 7: EBIT margin of 26% in H1: ~70 basis points negative impact from currencies
EBIT margin of 26%1 in H1: ~70 basis points negative impact from currencies and ~40 basis points negative impact from Kerecis H1 2025/26 EBIT margin development before special items (%) H1 2025/26 highlights • Gross margin of 67%, compared to 68% last year. • Negative impact from currencies (~60 bas
Slide 8: Strong FCF-to-sales ratio at 20% in H1 2025/26 vs. 15% last year
Strong FCF-to-sales ratio at 20% in H1 2025/26 vs. 15% last year1: positive development in working capital and lower net financial items FCF development1 H1 2025/26 highlights • Adjusted FCF in H1 2025/26 was DKK 2,816 million, or a 33% increase, while 93 89 Adjusted FCF-to-sales ratio was 20%, comp
Slide 9: FY 2025/26 financial guidance: Organic growth revised to 5-6%
FY 2025/26 financial guidance: Organic growth revised to 5-6% and EBIT growth* revised to ~5%. ROIC** now expected at ~15% Organic revenue growth 5-6% Reported revenue growth in DKK Around 3% EBIT growth* in constant currencies Around 5% ROIC** Around 15% Capex-to-sales ratio Around 5% Effective tax
Slide 10: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding